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Abbreviations: ECM; extracellular matrix, ILK-1; integrin linked-kinase 1, GSK3b; 
Glycogen synthase kinase 3 beta, MAPK; mitogen activated protein kinase, FAK; focal 
adhesion kinase, TRAMP; transgenic adenocarcinoma of the mouse prostate, BSA; 
bovine serum albumin, SDS-PAGE; sodium dodecyl sulfate polyacrylamide gel 
electrophoresis, pEGFP; red-shifted variant of wild-type Green fluorescence protein, 
DAPI; 4',6-diamidino-2-phenylindole, poly-HEMA; poly (2-hydroxyethyl) methacrylate, 
TBST; TRIS buffered saline with Tween 20, BPH; Benign Prostate Hyperplasia  
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ABSTRACT 
Talin1 is an integrin regulatory protein that mediates integrin interactions with the 
extracellular matrix (ECM). This study investigated the significance of talin1 in prostate 
cancer progression to metastasis in vitro and in vivo. Talin1 overexpression enhanced 
prostate cancer cell adhesion, migration and invasion by activating survival signals and 
anoikis resistance. ShRNA-mediated talin1 loss led to a significant suppression of 
prostate cancer cell migration and transendothelial invasion in vitro and a significant 
inhibition of prostate cancer metastasis in vivo. Talin1 regulates cell survival signals via 
phosphorylation of focal adhesion kinase (FAK) and AKT. Targeting AKT activation led 
to a significant reduction of talin1-mediated prostate cancer cell invasion. Furthermore, 
talin1 expression was determined by immunostaining in prostate tissue from the TRAMP 
mouse model and in human prostate cancer specimens. Talin1 levels directly correlated 
with prostate tumor progression to metastasis in TRAMP mice. Talin1 profiling in human 
prostate specimens revealed a significantly higher expression of cytoplasmic talin1 in 
metastatic tissue compared to primary prostate tumors and benign prostate tissue 
(P<0.0001). This evidence suggests a potential value for talin1 as a marker of prostate 
cancer metastasis and implies that disrupting talin1 mediated signaling may have 
therapeutic significance in the treatment of metastatic disease.   
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INTRODUCTION 
 
Cancer metastasis is a multistep and complex process that involves dissociation of 
the tumor cells from the organ of origin, degradation of the extracellular matrix (ECM), 
cell migration, anchorage-independent growth, apoptosis evasion, angiogenesis, invasion 
of surrounding tissues, cell adhesion, movement and colonization to distant sites in the 
body1. Human prostate cancer progression to advanced metastatic disease is associated 
with relapse to a hormone-refractory state due to impaired apoptotic response to androgen 
ablation. Androgen-independent prostate cancer cells become resistant due to roadblocks 
in apoptosis and depending on the interactions with the tumor microenvironment, acquire 
invasive and metastatic properties2. Both tumor epithelial and endothelial cells require 
attachment to the ECM for survival; commonly upon loss of adhesion, cells undergo 
detachment-induced cell death, or anoikis. Anoikis, a unique phenomenon of apoptosis 
consequential to insufficient cell-matrix interactions3,4, is recognized as a significant 
player in tumor angiogenesis and metastasis5. During metastatic progression, cells are in 
a dynamic state lacking firm attachment to the ECM and susceptible to anoikis5. 
Resistance to die via anoikis dictates tumor cell survival and provides a molecular basis 
for therapeutic targeting of metastatic prostate cancer. Integrin-linked kinase (ILK) has 
been recognized as contributor to anoikis resistance via its ability to regulate several 
integrin-mediated cellular processes including cell adhesion, fibronectin-ECM assembly 
and anchorage-dependent cell growth6-8.   
Integrins are cell membrane receptors that mediate the functional interactions 
between a cell and the ECM, thus serving as bidirectional transducers of extracellular and 
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intracellular signals, ultimately regulating adhesion, proliferation, anoikis, survival and 
tumor progression9-12. Talin1 is a cytoskeletal linker protein that interacts with the 
cytoplasmic domain of integrins leading to integrin activation10,13 and regulates their 
adhesion to extracellular ligands14. Talin1-deficient mice exhibit failure of integrins to 
aggregate into clusters and connect to the cytoskeleton, resembling the integrin deficient 
phenotype, and supporting that integrin function is talin1-dependent15. Furthermore 
recent studies in Drosophila, demonstrate that talin1 suppresses E-cadherin expression 
independent of integrin16, indicating a role for talin1 distinct from the integrin-dependent 
mechanism. The contribution of talin1 to cancer development and progression has not 
previously investigated.   
The present study investigated the role of talin1 in prostate cancer progression to 
metastasis. Our results indicate that talin1 engages the PI3-K/AKT signaling as the 
intracellular survival mechanism to confer anoikis resistance and promote invasion of 
human prostate cancer cells. Moreover, talin1 profiling in human prostate cancer 
specimens revealed a significantly increase in talin1 expression in metastatic prostate 
compared to benign and primary prostate tumors.  
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RESULTS 
 
The effect of talin1 overexpression on the adhesion ability and migration potential 
of prostate cancer cells were first examined in vitro. GFP-talin1 stable transfectants of 
human PC-3 prostate cancer cells were generated, since this cell line expressed very low 
endogenous talin1 levels (Fig. 1A, and Sup1). Overexpression of talin1 significantly 
increased both the adhesion (Fig. 1B) and migration potential of prostate cancer cells 
compared to vector control cells (Fig. 1, panels C, D). We subsequently determined the 
consequences of talin1-overexpression on the invasion potential of prostate cancer cells 
through an endothelial cell monolayer. The trans-endothelial migration (TEM) assay was 
performed using the human brain membrane endothelial cells (HBMEC). Talin1 
overexpression led to a significantly increased prostate cancer cell invasion through 
endothelial cell monolayer (Fig. 1, panels E and F).  
Prostate tumor epithelial cell survival requires continuous attachment to the ECM 
and it is recognized that fibronectin, laminin and collagen participate in the formation of 
attachment plagues linked to the actin cytoskeleton. The impact of talin1 loss on prostate 
cancer cell adhesion was examined by generating ShRNA-talin1 stable transfectants in 
DU-145 prostate cancer cells that are characterized by high endogenous talin1 expression 
(Sup. 1). As shown on Fig 2A, ShRNA silencing of talin1 effectively reduced talin1 
expression in DU-145 cells (>80%). Talin1 silenced DU-145 cells exhibited a reduced 
ability to adhere to different ECM components including collagen, laminin and 
fibronectin (Fig. 2B). Furthermore loss of talin1 led to significant reduction in the 
migration potential compared to vector control cells (Fig. 2, panels C and D). 
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Examination of the invasion ability of talin1-silenced transfectants through an endothelial 
cell monolayer revealed a significant suppression (Fig. 2, panels E and F).  
The mechanism via which talin1 activates intracellular signals was subsequently 
examined in the context ECM-epithelial cell interaction. We focused on the FAK/AKT 
and the intracellular MAP kinase signaling pathway, as both mechanisms have been 
implicated in integrin-focal adhesion dependent signals17. Activation of FAK due to 
phosphorylation (Y397) was observed on collagen attachment conditions, while it was 
more prominent on fibronectin coated ECM in talin1 overexpressing cells relative to 
control cells (Fig. 3A). Talin1 overexpression also resulted in a marked activation on 
phosphorylation of AKT (Ser473) under fibronectin-attachment conditions, while only a 
modest activation of p44/42 MAP kinase was observed (Fig. 3A). The expression level of 
integrin-dependent signals was confirmed by confocal microscopy (Fig. 3B). Talin1 
overexpressing cells exhibited increased expression of P-FAK, P-AKT and P-MAPK 
proteins relative to vector control cells upon fibronectin-aatachment  conditions (Fig. 3B).  
Furthermore, talin1 overexpression enhanced AKT phosphorylation within the first 3hrs 
of incubation (Fig. 3, panels C, D), an change that temporally preceded a significant 
increase in phosphorylated FAK and MAPK (Fig. 3C, D).  
The effect of  talin1 on integrin-focal adhesion complex signaling interactions 
was subsequently investigated, by examining the direct binding of talin1 to integrn β3, a 
key talin1 binding partner 18. To this end we used the DU-145 cell line, which exhibits 
high endogenous expression of integrin β3 (data not shown). Talin1 silencing 
significantly reduced the protein binding to integrin β3, as well as the focal adhesion 
partners, FAK and SRC (Fig. 3E).  The reduced binding of SRC upon talin1 loss, led us 
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to determine the role of ILK-1, a protein that regulates SRC binding in response to 
integrin activation (Fig. 3F). Immunoprecipitation by integrin β3 revealed a significant 
decrease in ILK-1 interaction in talin1-silenced prostate cancer cells. 
Immunoprecipitation by ILK-1 also revealed a similar pattern, indicating that talin1 loss 
inhibited ILK-1 binding to integrin β3 complex (Fig. 3F).  
In view of the emerging role of anoikis resistance as a critical contributor to 
metastasis during cancer progression5, we subsequently examined the impact of talin1 
overexpression on cell viability under ECM independent cell-suspension conditions, 
characteristic of anoikis. After plating on either fibronectin-coated matrix or the 
nonadhesive polyhydroxyethylmethacrylate (poly-HEMA), cells undergoing apoptosis 
were detected using the Annexin V staining. As shown on Figure 4A, talin1 did not exert 
a significant apoptotic effect under adherent conditions; however, in cell-suspension 
conditions, talin1 overexpressing prostate cells exhibited a significantly reduced 
apoptosis (Fig. 4A). Moreover, talin1 overexpressing cells exhibited an activation of 
FAK (Y397), AKT (Ser473) and SRC, but the response was weaker compared to the one 
obtained under fibronectin conditions (Fig. 4B). A modest activation of p42/44 MAPK 
was also observed in talin1 overexpressing cells. A time-course analysis of the anchorage 
independent phosphorylation of these proteins revealed a significant increase in 
phosphorylation of FAK, AKT and SRC in talin1-overexpressing cells within 6-24hrs 
(Fig. 4, panels C and D). Since ILK-1 mediated signaling is involved in anoikis 
resistance19,20, we subsequently examined the phosphorylation of GSK3-b as a direct 
down stream signals of ILK-1. As shown in Fig. 4, there is an increased phosphorylation 
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of GSK-3b in non-adherent conditions in talin1 overexrpessing cells that was temporally 
associated with reduced amount of cleaved caspase-3 (Fig.4, panels E and F).  
To determine whether AKT activation is an integral part of talin1 intracellular 
signaling, the consequences of AKT inhibition on talin1-mediated biological effects were 
examined. Since AKT activation comprises a critical signaling effector in anoikis 
resistance21 we next studied the impact of talin1 overexpression on anoikis. The data on 
Figure 5A indicate that inhibiting AKT had no significant effect on the adhesion potential 
of GFP-talin1 prostate cancer cells on neither fibronectin nor laminin-coated matrix.  In 
the presence of the AKT inhibitor, a significant suppression of both the migration 
potential (Fig. 5, panels B, C) and invasion ability (Fig. 5, panels D and E) was detected 
in talin1 overexpressing prostate cancer cells (P<0.01).   
Resistance to anoikis is being recognized as a potentially important mechanism 
underlying tumor cell metastatic dissemination5; thus in subsequent experiments we 
pursued the functional characterization of talin1 in determining the metastatic potential of 
prostate cancer cells in vivo. Talin1 loss in prostate cancer cells led to a significantly 
reduced number of metastatic tumor lesions to the lungs compared to control cells (Fig. 
6A). The significance of talin1 during in vivo tumorigenesis was investigated in the 
transgenic adenocarcinoma mouse prostate (TRAMP) mouse model of prostate cancer 
progression. As shown on Figure 6B, talin1 immunoreactivity was primarily detected 
among the glandular epithelial cells in the TRAMP prostates. Talin1 levels progressively 
increased with increasing age of TRAMP mice (6 - 27wks) [Fig. 6, panels (iii-vi)]. There 
was weak talin1 immunoreactivity in prostate tissue from wild-type (WT) control mice, 
while the intensity of talin1 staining was stronger in primary prostate tumors, with the 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
09
.3
05
9.
1 
: P
os
te
d 
10
 A
pr
 2
00
9
 10
highest detected in liver metastases (Fig. 6 ii). Quantitative analysis revealed a 2-fold 
increase in talin1 expression in prostate tumors derived from 12wk TRAMP mice, 
compared to the 6wk old TRAMP prostates (Table 1). By 27 wks of age, upon time 
TRAMP mice exhibit a highly aggressive prostate tumor phenotype (grade 4.5-5), talin1 
immunoreactivity increased dramatically (Fig. 6), a change that reached a statistical 
significance (<0.01, Table 1).    
To determine whether talin1 might have a potential value for predicting human 
prostate cancer progression to metastastic disease, we conducted an 
immunohistochemical staining for talin1 in human prostate tissue specimens. Talin1 
expression was analyzed in human prostate tissue specimens from normal, BPH, primary 
tumors (Gleason 6-9) and metastatic tumors (Table 2). Detection of immunoreactivity 
was followed by automated quantitative analysis to measure the cytoplasmic levels of 
talin1. A representative picture of normal prostate, BPH, primary prostate tumor and 
metastatic lesion to the lymph node is shown on Figure 7 (Panel A).  Cytoplasmic talin1 
was significantly higher in metastases than in primary tumors and both were significantly 
elevated compared to normal prostate tissue (P<0.0001, P<0.0001, respectively). These 
findings suggest that talin1 expression is positively associated with human prostate 
cancer progression to metastatic disease. Normal areas of prostate adjacent to tumor foci 
expressed lower talin1 levels compared to the remaining normal prostate tissue (Table 1). 
Talin1 expression detected in BPH specimens was comparable to those detected in 
normal prostate tissue.  
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DISCUSSION  
 
The present study identifies talin1 as a novel regulator of prostate cancer cell 
invasion and metastatic potential, via its ability to enhance survival signals and confer 
anoikis resistance. Several key survival signaling pathways including AKT, FAK and 
Ras/Erk are activated by integrin adhesion and detachment from the ECM results in their 
inactivation17. Anoikis, (detachment from the ECM), results in activation of pro-apoptotic 
proteins and inhibition of anti-apoptotic proteins22,23. Our findings demonstrate that talin1 
overexpression significantly enhanced the migration and invasion potential of human 
prostate cancer cells via an AKT-dependent mechanism. In contrast, loss of talin1 led to a 
diminished invasion potential and in vivo metastatic ability of prostate cancer cells. 
These results are in accord with a previous screening reporting that highly metastatic 
cells expressed significantly high levels of talin1 (>16 fold, out of 440 proteins screened) 
compared to less metastatic cells24. Interestingly enough, in primary prostate cancer cells, 
talin1 mRNA has been shown to be downregulated by androgens25. Taken together this 
evidence supports an indirect link between talin1 and prostate cancer metastasis and 
emergence to androgen-independence.  
Overexpressing talin1 in prostate cancer cells led to activation of FAK/AKT 
signaling via both an ECM-dependent and -independent mechanism. Gaining strong 
support from evidence that AKT survival signaling is causally linked to anoikis resistance 
in detached cells26,27, our data indicate that talin1 promotes prostate cancer cells to 
metastasize by enhancing their invasive properties and survival after detachment from the 
primary tumor site via activation of FAK and AKT signaling. This resonates with a 
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similar role assigned to another key focal adhesion protein, paxillin in different tumors. 
Indeed, overexpression of paxillin correlates with metastatic and invasion properties in 
hepatocellular carcinoma 28. Recruitment of FAK and paxillin to β1 integrin promotes 
cancer cell migration through MAPK activation 29. The present findings suggest that 
talin1 might not be causally involved in primary tumor development, but rather in 
promoting local invasion, as well as distant metastasis, via conferring resistance to 
anoikis. Such anoikis regulation by talin1, is not a selective advantage during tumor 
growth in an ECM-rich microenvironment; rather during the invasion through vasculature 
during metastasis, resistance to anoikis could predict a greater ability to form metastatic 
lesions. A similar functional contribution in strongly enhancing metastasis but not 
primary tumor growth, was demonstrated by the apoptotic suppressor of cytoskeleton-
dependent death, Bcl-Xl during mammary carcinogenesis. 30 
Mechanistic dissection revealed that talin1 interferes with ILK-1 binding to 
integrin β3 subunit. ILK is a serine/threonine protein kinase, that interacts with 
cytoplasmic domain of β1-integrin and β3-integrin and has been functionally linked to 
integrin and Wnt signaling pathways7,19,31. Upon cell adhesion, ILK is transiently 
activated and directly phosphorylates PKB/AKT and glycogen synthase kinase-3 
(GSK3)6; in contrast, inhibiting ILK in cancer cells inhibits AKT phosphorylation and 
cell survival; taken together these lines of evidence point to a potentially critical role for 
ILK in signaling anoikis resistance and cell survival mechanisms. Indeed, the present 
results indicate that talin1 loss partially abrogates ILK-1 binding to integrin β3, 
implicating ILK-1 as an intracellular effector of talin1 signaling, activated upstream of 
the AKT survival pathway. This in vitro evidence suggests that talin1 confers anoikis 
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resistance (non-adherent) and mediates direct ECM-epithelial interaction (adherent 
conditions). Based on these findings, we propose that such an effect of talin1 on anoikis 
might be responsible for the acquisition of the primary tumor cell invasive and metastatic 
properties leading to prostate cancer metastasis (Fig. 8). In this mechanistic scenario, 
under adherent conditions, talin1 facilitates integrin signaling and its link to the ECM. 
Talin1 binding to β integrin recruits the focal adhesion proteins ILK, FAK and SRC, 
towards activation of the downstream signals such as AKT and ERK. This signaling 
activation promotes cell survival, invasion and angiogenesis. Under non-adherent 
conditions, talin1 stimulates FAK and SRC independent of integrin signaling and confers 
resistance to anoikis, leading to metastatic spread of prostate cancer cells (Fig. 8). The 
concept derives strong support from our in vivo findings. Analysis of talin1 protein 
expression in the TRAMP model of prostate tumorigenesis, indeed demonstrated a 
positive correlation between talin1 immunoreactivity and prostate cancer progression to 
metastasis. A greater than 2-fold increase in talin-1 expression was detected in prostate 
tumors from 12wk TRAMP mice (compared to 6wk TRAMP); talin1 levels were further 
elevated with tumor progression to advanced metastatic disease (27wks) (Table 1).     
Of major clinical relevance is immunostaining screening of talin1 in human 
prostate specimens indicating a significant increase in talin1 expression in primary 
tumors and metastatic prostate cancer, compared to BPH and normal prostate. The 
metastatic specimens exhibited significantly higher talin1 levels compared to primary 
prostate tumors, implicating an involvement of talin1 in the metastatic process. Talin1 
expression was considerably higher in poorly differentiated prostate tumors (Gleason >8) 
compared to moderately differentiated (tumors Gleason 6/7).  Moreover, there was an 
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inverse correlation between talin1 increased expression and E-cadherin loss in human 
prostate tumors and metastastic specimens (data not shown). These results support that 
talin1 may have diagnostic value in prostate cancer detection and clinical outcome. 
Ongoing studies focus on a correlation between talin1 expression with serum PSA levels, 
Gleason grade and patient (disease-free) survival in a large cohort of prostate cancer 
patients, which may define the value of talin1 as a cancer metastasis marker.  
In summary, the evidence presented supports a function for talin1 in regulating 
prostate tumor cell invasion, and anoikis resistance towards metastasis. Future studies 
will pursue the generation of a conditional knockout mouse model of talin1, selectively 
targeting talin1 gene expression in prostate epithelial cells and its crossing with a 
transgenic mouse model of prostate cancer (since the homozygous talin1 knockout mice 
are embryonically lethal11). Ongoing efforts focus on characterizing talin 1 interactions 
with other binding partners such as paxillin, vinculin, and the impact of such interactions 
on the phosphorylation status of critical downstream signaling effectors in the context of 
integrin-related signal transduction. Further dissection of the contribution of talin1 to 
anoikis resistance mechanisms driving tumor and endothelial cell survival, may provide 
new signaling platforms for therapeutic targeting of metastatic prostate cancer.  
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MATERIALS AND METHODS 
 
Cell Culture and Transfections: Human prostate cancer cell lines PC-3, DU-145, 
LNCAP, CWR-22, were obtained from the American Type Tissue Culture Collection 
(Rockville, MD) and cultured in RPMI-1640 (Invitrogen, Carlsbad, CA) containing 10% 
fetal bovine serum (Invitrogen) and antibiotics, PenicilinG/Streptomycin (50μg/ml). 
Human vascular endothelial cells (HUVEC) and Human Microvascular Brain Endothelial 
cells (HBMEC) were cultured in endothelial basal medium (EGM-2) (Cambrex, East 
Rutherford, New Jersey). Transfection was performed using LipofectaminTM 2000 
reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. PC-3 cells 
were transfected with pEGFP vector or GFP-Talin1 plasmids) and cloned under G418 
selection (Geneticin, Gibco Brl, Grand Island, NY). For silencing talin1 expression in 
prostate cancer cells, the ShRNA talin1 vector (GIPZ ShRNAmir talin1) was obtained 
from Open Biosystems (Huntsville, AL). ShRNA talin1 DU-145 cells were selected 
using puromycin (a resistance marker) and individual clones were expanded. 
Attachment Assay: Cells were seeded in six-well plates (5x104cells/well) coated 
with fibronectin (BD Biosciences Discovery Labware, Bedford, MA). Following a 10-
min attachment period, attached cells were fixed with methanol (100%) and stored at 4°C 
in PBS for image analysis. Cells were counted in three x100 fields/well.  
Migration Assay: Cell cultures (at 75% confluency) were subjected to wounding 
as previously described32. At 24 and 48hrs post-wounding cells migrating to the wounded 
areas were counted under the microscope. 
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Transendothelial Migration (TEM) Assay: Sterile (12mm diameter) glass 
coverslips were coated with Matrigel (Becton Dickson, Franklin Lakes, NJ). Coverslips 
were then seeded (at a density of 6.25x104 HBMEC) to form a complete monolayer. Cells 
were allowed to adhere and spread on the Matrigel for 24hrs prior to initiation of the 
migration assay. PC-3 and DU-145 cells were resuspended in EGM-2MV (Cambrex) and 
added to the HBMEC monolayer (8x103cells/coverslip), for 12hrs. Cells were 
subsequently fixed in paraformaldehyde (2% in PBS) (10mins at room temperature) and 
washed with PBS. Nuclei were stained with DAPI Nucleic Acid Stain (Molecular Probes, 
Eugene, OR).  Slides were visualized and examined under confocal microscopy.   
Western Blot Analysis: Protein expression was determined by immunoblotting 
using the following specific antibodies: The human polyclonal rabbit talin1 antibody was 
generated and provided Dr. Richard McCann. The antibodies against FAK, AKT, 
phospho-Akt(Ser473), p44/42-MAP kinase, phospho p42/44-MAP kinase, SRC, 
Phosopho-SRC(Tyro416), GSK3-b, phospho-GSK3-b and ILK-1 were obtained from 
Cell Signaling Technology (Beverly, MA); The phospho-FAK(Y397) was obtained from 
Sigma (St. Louis, MO). Protein levels were normalized to α-actin expression, detected by 
using the α-actin antibody from Oncogene Research Products™ (La Jolla, CA). Cell 
lysates were prepared in RIPA buffer [150 mmol/l NaCl, 50 mmol/l Tris (pH 8.0), 0.5% 
deoxycholic acid, 1% NP-40 with 1 mmol/l phenyl methyl-sulfonyl fluoride]. Protein 
content was quantified using the bicinchoninic acid (BCA) protein assay kit (Pierce, 
Rockford, IL) and protein samples (30µg) were subjected to SDS-PAGE and transferred 
to Hybond-C membranes (Amersham Pharmacia Biotech, Piscataway, NJ). Membranes 
were blocked in 5% milk in TBS-T (TBS containing 0.05% Tween 20) (1 hr at room 
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temperature) and following incubation with the respective primary antibody (overnight at 
4°C), membranes were exposed to species-specific horseradish peroxidase–labeled 
secondary antibodies. Signal detection was achieved with SuperSignal West Dura 
Extended Duration Substrate (Pierce) and visualized using a UVP Imaging System. Fold 
change in specific protein expression was determined on the basis of α-actin expression 
as a loading control.  
Immunoprecipitation: DU-145 cells, ShVector control and ShTalin1 
transfectants were lysed in RIPA buffer. Total protein concentration was quantified (as 
described above) and protein samples (100µg) were incubated overnight at 4°C with the 
specific antibody. Following incubation of lysates with Protein G Plus/Protein A agarose 
beads (30µl) for 3hrs at 4°C, beads were washed in RIPA buffer, subjected to SDS-
PAGE analysis, and transferred to nitrocellulose membranes (Amersham Pharmacia).   
AKT inhibitor: The AKT inhibitor; 1L6-Hydroxymethyl-chiro-inositol-2-(R)-2-
O-methyl-3-O-octadecyl-sn-glycerocarbonate, was purchased from Calbiochem 
(Gibbstown, NJ). The concentration of inhibitor used was 10μM  as previously reported 33.  
Apoptosis Evaluation: Cells were harvested in EDTA buffer (0.5mM) and 
incubated in Hanks Balanced Salt Solution (HBSS) supplemented with 2% BSA and 
0.01% sodium azide (30mins at 4°C). Cells were subsequently fixed in 4% (w/v) 
formaldehyde in PBS, and exposed to Annexin-V (R&D Systems, Minneapolis, MN) 
followed by FITC-conjugated secondary antibody. Analysis of Annexin V fluorescence 
was performed using flow cytometry (Partec, Munster, Germany).  
Confocal Laser Scanning Microscopy: PC-3 prostate cells were cultured on 
four-chamber culture slides (BD Falcon, Bedford, MA). Cells were fixed in 4% 
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paraformaldehyde and permeabilized with 0.2% Triton X-100. Cells were exposed to the 
specific antibody, incubated with Alexa 546-conjugated goat anti-rabbit and mouse 
(Invitrogen), and were subsequently examined by confocal laser scanning microscopy 
(Leica Microsysterms, Wetzel, Germany) with constant intensity settings. Images were 
analyzed with Leica software (Leica Microsysterms).  
Cell Cycle Arrest-Flow Cytometric Analysis: Cells were fixed with 70% 
ethanol (30mins at 4°C) and were subsequently stained with Propidium iodide (50μg/ml) 
containing 20μg/ml of RNase (30mins at room temperature). Cell cycle progression was 
analyzed via fluorescence-activated cell sorting (FACS) using the Partec Flow Max.  
Anoikis Evaluation: Cells were plated on dishes coated with either fibronectin or 
the nonadhesive polyhydroxyethylmethacrylate (poly-HEMA) and incubated for 24hr. 
Cells undergoing apoptosis were detected using the Annexin V immunofluorescence 
approach and flow-cytometric analysis. Western blotting was used to determine the 
expression of key apoptosis regulators after overexpression and silencing of talin1 in 
prostate cancer cells.   
In Vivo Experimental Metastasis Assay: Human prostate cancer cells were 
injected (2x106 cells /80μl of PBS) in the tail vein of male nude mice (4–6 wks). After 5-
weeks mice were sacrificed and the lungs and liver were surgically excised and examined 
for metastatic lesions under a dissecting microscope (40x).  
TRAMP Transgenic Mouse Model: The TRAMP mice (C57BL/6J) are 
transgenic mice that express SV40T/t antigens under the prostate specific rat probasin 
promoter34,35. TRAMP transgenic males develop prostate adenocarcinoma in a manner 
resembling the clinical progression of human prostate cancer from intra-epithelial 
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neoplasia to androgen-independent metastatic tumors. Histological hematoxylin and 
eosin (H&E) sections of prostate tissues from TRAMP/+/+ male mice were evaluated by 
two independent investigators (S.S. and N.K.) to confirm the pathological grade. Wild-
type male mice (C57BL/6) of comparable age groups (6-29wks) served as controls. The 
histopathological grading of prostatic tumors was conducted using a standard grading 
scale in TRAMP mice.  Flat lesions and focal cell piling (grade 2.0-2.2) were observed in 
the majority of 12wks-old TRAMP mice (Table 1). In 20wk-27wk-old TRAMP mice, 
prostates exhibited focal cribriform lesions protruding into the lumen (grade 3-5), 
representing tumor progression to advanced disease.  
Prostate serial sections from the normal wild type and the TRAMP tumors of 
increasing grade and metastatic lesions (5μm), were subjected to immunohistochemical 
analysis for talin1 using the talin1 polyclonal antibody (generously provided by Dr. 
McCann). Slides were examined under a Nikon fluorescence microscope (Nikon Inc., 
Melville, NY). Values were determined in a semiquantitative fashion, incorporating both 
the intensity of staining and the number of positively stained epithelial cells36. Briefly, 
the staining intensity (I) was graded as 0, absent; 1, weak; 2, moderate; or 3, strong. The 
proportion (P) of positive epithelial cells (0.0 to 1.0) with the staining intensity was 
recorded; A score for each histological grade (H) was determined as the product of 
intensity and proportion (H = I × P).  
Human Prostate Specimens: Human prostate tissue microarrays (TMAs), from 
patients with primary and metastatic prostate tumors were subjected to immuno-profiling 
for talin1 expression (subcontract with the Department of Pathology, University of 
Pittsburgh). Computer-image analysis was used to determine the level of talin1 
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expression in the prostate tissue specimens: 42 normal prostate; 101 normal areas 
surrounding malignant tissue; 56 BPH areas; 31 prostate primary tumors (Gleason Score 
range 6-9); and 74 metastatic lesions.   
Statistical Analysis: One-way analysis of variance (ANOVA) was performed 
using the StatView statistical program to determine the statistical significance between 
values (P value less than 0.05). Tissue immunoreactivity was analyzed and interpreted 
according to previously published protocols37. 
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FIGURE LEGENDS 
 
 
Figure 1. Panel A, Generation of PC-3 Stable Transfectants Expressing GFP-
talin1. pEGFP-talin1 and pEGFP vector stable transfectants were established in PC-3 
cells selected under G418 Geneticin s a selection marker. The bands indicate GFP-talin1 
(280kDa) and GFP-vector protein (28kDa) respectively. Panel B, pEGFP-talin1 mediated 
enhanced adhesion ability in PC-3 cells. The adhesion potential was comparatively 
analyzed in laminin or fibronectin-coated plates in PC-3 pEGFP vector control and PC-3 
GFP talin1 cloned transfectants. Panel C, Talin1 expression enhances migration potential. 
PC-3 cells were subjected to wounding and migrating cells were counted under the 
microscope in three independent fields (40x)/well (3 wells/condition)(Panel D). Panels E, 
and F, Talin1 enhanced the migration potential through the endothelial monolayer. The 
transendothelial migration assay was performed using HBMECs, and either PC-3 GFP-
vector or PC-3 GFP Talin1 expressing cells as described in “Materials and Methods”.   
 
Figure 2. Effect of Talin1 loss on Prostate Cancer Cell Migration and 
Invasion. Panel A, Talin1 ShRNA stable cell line in DU-145 cells.   ShRNA talin1 stable 
cell line is established in DU145 cells. Panel B, ShRNA vector and ShRNA-talin1 
transfectant cells were comparatively analyzed for their adhesion potential as described 
above. Panel C, Talin1 silencing reduces DU-145 cell migration ability. Cells were 
subjected to wounding and migration potential was evaluated; the number of migrating 
cells was counted under the microscope in three independent fields (40x) per well (3 
wells/condition) (Panel D). Panel E, Loss of talin1 inhibits prostate tumor cell invasion. 
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Transendothelial migration assay were conducted using HBMEC (human brain 
microvascular endothelial cell) DU-145 vector and ShRNA Talin1 stable cell line. The 
number of invading cells (red) was determined under confocal microscopy (Panel F). 
Blue represents DAPI nuclear staining.  
 
Figure 3. Talin1 Mediates ECM-dependent Activation of FAK/AKT Pathway. 
Panel A, pEGFP-talin1 and vector-transfected PC-3 cells were allowed to adhere on 
either collagen or fibronectin plates. After 6hrs, cells are collected and subjected to 
western blot analysis. Levels of phosphorylated AKT (Ser473), FAK(Y397) and MAPK 
proteins as wells as total protein were detected using respective antibodies. Panel B,. 
Expression of p-FAK, p-AKT and p-MAPK pEGFP-talin1 and vector-transfected PC-3 
cells (on fibronectin), were examined using specific antibody with Alexa 546 
fluorescence (Red). Nuclei were stained with DAPI (Blue). (x400 magnification). Panel 
C, Phosphorylation of AKT (Ser473), FAK(Y397) and MAPK was analyzed after 
adherence to fibronectin as indicated (3-24hr). Panel D, Quantification of 
phosphorylation status of AKT (Ser473), FAK(Y397) and MAPK was determined by 
densitometry. Panel E, ShTalin1 DU-145 cells were subjected to immunoprecipitation 
using the integrin β3 antibody. Talin1, total FAK and SRC binding was detected using 
the respective antibodies. Panel F, Cells (as above) were subjected to 
immunoprecipitation using monocolonal integrin β3 antibody or polycolonal ILK-1 
antibody. Binding of ILK-1 or integrin β3 was determined using the respective antibodies. 
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Figure 4. Talin1 Mediates Anoikis Resistance. Panel A, pEGFP-talin1 and 
vector PC-3 cells were kept in suspension conditions for 24hr using Poly-HEMA coated 
plates. Apoptosis was determined by Annexin-V immunofluorescence and the % of 
Annexin-V positive cells over the total number of cells are shown on the barograph. 
Panel B, After 24hr of cell suspension, cells are lysed and subjected to Western blot 
analysis. Phosphorylation of AKT (Ser473), FAK (Y397) and p42/44MAPK together 
with total proteins were detected using respective antibodies. Panel C, Phosphorylation 
of AKT (Ser473), FAK (Y397) and SRC and total protein expression was studied during 
various time points (3-24hr). Panel D, The phosphorylation status of AKT (Ser473), 
FAK (Y397) and SRC was analyzed by densitometry. Panel E, Phosphorylation of 
GSK3b and total GSK3-b and cleaved caspase-3 were determined during the same time 
course (3-24hr). The fold-changes relative to vector control are shown on Panel F.  
 
Figure 5. Consequences of AKT Inhibion on Adhesion, Migration and 
Invasion of Talin1 Overexpressing Prostate Cancer Cells. Panel A, The impact of 
AKT signaling inhibition on the adhesion ability of GFP-talin1 stable PC-3 tranfectants 
to collagen, laminin or fibronectin coated-plates was determined as described in 
“Materials and Methods”. Panel B, Prostate cancer cells were subjected to wounding and 
migrating cells (GFP-talin1 or GFP vector PC-3 cells) were evaluated at 24 and 48hr 
post-wounding, in the presence or absence of AKT inhibition.  Three independent 
fields/well were counted (40x). Panel C, Transendothelial migration assay was 
conducted using HBMEC under conditions of AKT inhibition. The green color indicates 
migrating prostate cancer cells, the blue color indicates the nuclear DAPI staining.  
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Figure 6.  Panel A, Talin1 Loss Suppresses Prostate Cancer Cell Metastasis. 
Nude mice were injected with prostate cancer cells, DU-145 ShVector, n=6 and DU-145 
shRNA talin1, n=5, (2x106/mouse) in the tail vein. Five (5) weeks post-inoculation, the 
lungs were surgically dissected and metastastic lesions were evaluated. Silencing talin 1 
resulted in a significantly reduced number of metastatic lesions to the lungs (P =0.028).   
Panel B, Talin1 Immunostaining in TRAMP Mouse Model of Prostate 
Adenocarcinoma Progression. Talin1 immunreactivity was analyzed in paraffin-
embedded prostate tissue specimens from TRAMP mice and control age-matched mice 
(6-27 wks). Pathological grading of the tumors was performed as described in “Materials 
and Methods”. A strong immunoreactivity for talin1 was detected in prostate tumors 
derived from both 19wk and 27wk TRAMP mice, subpanels (iv) and (v), respectively. 
Sub-panel (ii) represents a metastatic lesion to the liver in a TRAMP mouse (27wks).  
 
Table 1. Expression of Talin1 in Prostate Tumors from TRAMP Mice. The 
intensity of IHC staining (H) was calculated by P=Percentage of staining x I intensity (1-
3). The numerical data reveal a positive correlation between increasing tumor grade and 
increased talin expression. Talin1 expression was significantly increased prostate tumor 
progression to metastasis. (*) and (**) indicates statistical difference at p value<0.05 and 
<0.01, respectively, compared to specimens from wild-type control mice. 
 
Figure 7. Expression of Talin1 in Human Prostate Tissue. Talin1 
immunreactivity was analyzed in paraffin-embedded prostate tissue specimens from 
human prostate cancer patients as described in “Materials and Methods”.  A 
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representative image for talin1 immunoreactivity is shown in each developmental stage, 
including the normal prostate (i); BPH (ii); Prostate Primary Tumor (iii); Metastatic 
Prostate Cancer (iv).  
 
Table 2. Quantitative Evaluation of Talin1 Immunostaining in Human 
Prostate Tissue. Computer-image analysis was used to determine the level of talin1 
expression in the prostate tissue specimens. Specimens included normal prostate, normal 
tissue adjacent to tumor foci, benign prostate hyperplasia, BPH; primary prostate tumor 
and lymph node metastasis. (*) and (**) indicate statistical difference at p value<0.05 and 
<0.01, respectively, compared to normal prostate.  
Table 3. Association of Talin1 Expression and Gleason Score.  Primary 
prostate cancer specimens were classified as moderately (Gleason 6/7) and poorly 
differentiated tumors (Gleason >8; 8, 9, 8/9) and talin1 expression values were 
comparatively evaluated. (*) and (**) indicate statistical differences at p-value<0.05 and 
p<0.01, respectively, compared to moderately differentiated tumors (Gleason 6/7).  
 
Figure 8. Proposed Talin1 Signaling in Cancer Cells. Under adherent 
conditions, talin1 facilitates integrin signaling to the ECM. Talin1 binding to β integrin 
recruits the focal adhesion proteins ILK, FAK and SRC, towards acivtation of the 
downstream signaling. Subsequent activation of downstream AKT and ERK signals, 
promotes angiogenesis, cell cycle progression, cell survival and apoptosis resistance. 
Under non-adherent conditions, talin1 stimulates FAK/SRC and ILK-1/GSK3b related 
signals independent of integrin signaling and mediates anoikis resistance. 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4  
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Figure 5 
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Figure 6  
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
09
.3
05
9.
1 
: P
os
te
d 
10
 A
pr
 2
00
9
 35
Figure 7 
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Figure 8  
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Supplementary 1  
 
Supplementary 1:  Panel A, Expression of Talin1 in Human Prostate Cancer Cell 
Lines. Western blot analysis of talin1 basal levels of expression in various human 
prostate cancer cell lines as shown. Actin expression was used as a loading control. Cell 
lysates were subjected to SDS page and detected with the respective specific antibody. 
Panel B, mRNA expression profiling.  RNA samples from the various human prostate 
tumor epithelial cells were subjected to reverse transcription, and subsequent PCR using 
talin1 and 18S primers as described in “Materials and Methods”. Talin1 mRNA 
expression was normalized to 18S expression.  
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Supplementary 2 
 
  
Supplementary 2: Effect of Talin1 on G0-G1 Cell Population under Non-adherent 
Conditions.  GFP-Talin1 and GFP-vector transfected cells were incubated in non-
adherent poly-HEMA conditions for 24hr and subjected to cell cycle analysis using PI 
staining through Flow Cytometry. The sub G0-G1 populations are shown on Panel A. 
Panel B indicates the quantitative analysis of SubG0-G1 population.   
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